Three grants given researchers at two centres in Australia will advance work into ways of preserving nerve cells in people with ALS

Pharnext’s investigational oral combination therapy PXT864 prevents degeneration of motor neurons and their point of contact with...

Innovate UK has given a grant to Reflection Therapeutics to help fund research into new ways of protecting the nervous system from motor neu

AC Immune is planning to advance its investigational anti-TDP-43 antibody into clinical testing for neurodegenerative diseases, like amyotr

Aural Analytics, Inc., a privately-held digital health company developing the world’s most advanced suite of clinical-grade speech analytic

Kadimastem’s cell therapy candidate, AstroRx, significantly lower the rate of disease progression in people with amyotrophic lateral scleros

The gut microbiome in people with amyotrophic lateral sclerosis (ALS) is altered compared to healthy people, which includes an imbalance in

Orion Corporation’s oral therapy levosimendan (ODM-109) failed to preserve lung function and overall functionality in people with amyotrophi

Measurements taken of muscle using ultrasound could be useful in diagnosing or managing amyotrophic lateral sclerosis (ALS), a small study s

A new mutation in the FUS gene, which results in a shorter version of the FUS protein that cannot enter form the cell nucleus to work as it

Tofersen, Biogen’s investigational therapy for people with familial amyotrophic lateral sclerosis (ALS) caused by SOD1 gene mutations.

An FDA-approved diabetes drug shows early signs of promise against the most common genetic form of amyotrophic lateral sclerosis.

A comparison of amyotrophic lateral sclerosis (ALS) among U.S. military veterans found those who lived the longest with this disease.